Mannitol-L-DOPA Conjugates for Sustained Brain Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Parkinson's disease, such as L-DOPA administration, suffer from short pharmacokinetic parameters and intermittent dopaminergic stimulation, leading to motor complications and failure to address underlying pathology, while existing delivery methods like sustained release pills and intraduodenal delivery are inconvenient and unsatisfactory.
Innovation Solution
Conjugates of mannitol and L-DOPA, or DOPA decarboxylase inhibitors, are formed via hydroxyl groups to create ester bonds, allowing for continuous release and improved pharmacokinetics, reducing α-synuclein aggregation, and facilitating transport across the blood-brain barrier.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If L-DOPA is administered continuously to provide sustained dopaminergic stimulation, then motor complications are reduced and disease progression is slowed, but the pharmacokinetic parameters remain short and delivery methods become complex
Solution Approach 1:
The patent uses mannitol as an intermediary carrier molecule that conjugates to L-DOPA. This intermediary facilitates continuous delivery by exploiting the glucose transport mechanism across the blood-brain barrier, eliminating the need for complex external pumps or surgical implants while extending the duration of therapeutic action.
Solution Approach 2:
The conjugate system performs self-delivery by utilizing the body's own glucose transport mechanisms. The mannitol-L-DOPA conjugate is transported across the blood-brain barrier through glucose transporter proteins, requiring no external power source, pump, or surgical intervention, thus achieving continuous delivery with zero device complexity.
2Reliability
If L-DOPA is administered continuously to maintain therapeutic concentrations, then dopaminergic stimulation becomes continuous, but current delivery methods require surgery or external devices
Solution Approach 1:
Mannitol serves as a natural intermediary that enables continuous L-DOPA delivery through existing physiological transport pathways. This approach achieves reliable continuous stimulation without requiring surgery or external devices, making the system as easy to operate as taking an oral pill.
Solution Approach 2:
The mannitol-L-DOPA conjugate system performs multiple functions simultaneously: it delivers L-DOPA continuously, exploits natural glucose transport mechanisms, and requires no external power or surgical intervention. This multi-functionality achieves both reliability and ease of operation that current delivery methods cannot provide.
3Reliability
If L-DOPA is used to treat Parkinson's disease, then symptomatic improvement is achieved, but underlying pathology including α-synuclein aggregates is not addressed
Solution Approach 1:
The patent merges two therapeutic functions into a single conjugate system: L-DOPA provides symptomatic dopaminergic stimulation while mannitol simultaneously inhibits α-synuclein aggregation. This combination achieves both symptomatic relief and disease-modifying effects that separate treatments cannot accomplish.
Solution Approach 2:
The mannitol-L-DOPA conjugate system is versatile, simultaneously providing dopaminergic stimulation for symptom management and inhibiting α-synuclein aggregation to address underlying pathology. This multi-functionality allows a single treatment to tackle both symptomatic and pathological aspects of Parkinson's disease.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The conjugates provide sustained therapeutic effects, reducing motor complications and potentially slowing disease progression by maintaining consistent dopaminergic stimulation and inhibiting α-synuclein aggregation.
Implementation Method 1
the mannitol is conjugated to the carboxyl group of the one to six L-DOPA molecules via a hydroxyl group of the mannitol
Implementation Method 2
attaching L-DOPA to a sugar, such as glucose, exploits the glucose transport mechanism to facilitate transport across the blood-brain barrier
Implementation Method 3
Mannitol has been shown to inhibit aggregation of α-synuclein in PD animal models and its potential therapeutic effect on PD is via a distinct mechanism from that of L-DOPA
Data Source
AI summary
The present invention provides conjugates comprising a sugar such as mannitol and one or more L-DOPA and/or DOPA decarboxylse inhibitors including, inter alia, L-DOPA, carbidopa, benserazide, or a combination thereof, wherein the sugar is conjugated to the carboxyl group of the L-DOPA and/or DOPA decarboxylse inhibitor/s) via a hydroxyl group of the sugar. The present invention further provides related pharmaceutical compositions and methods of producing the conjugates, as well as methods of use for treating medical disorders responsive to dopamininergic stimulation such as movement disorders including, inter alia, Parkinson's Disease.